A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study).
Ryota ShibakiHiroaki AkamatsuTerufumi KatoKazumi NishinoMorihito OkadaTetsuya MitsudomiKazushige WakudaKenichi YoshimuraNobuyuki YamamotoKazuhiko NakagawaPublished in: Therapeutic advances in medical oncology (2021)
Ongoing phase III trials of adjuvant ICI allow the inclusion of patients with EGFR mutation, but our current trial will provide the earliest clinical data on the efficacy of platinum-doublet chemotherapy with atezolizumab.
Keyphrases
- phase iii
- phase ii study
- open label
- placebo controlled
- small cell lung cancer
- phase ii
- locally advanced
- clinical trial
- epidermal growth factor receptor
- early stage
- tyrosine kinase
- double blind
- study protocol
- palliative care
- rectal cancer
- electronic health record
- squamous cell carcinoma
- radiation therapy
- machine learning
- prognostic factors
- data analysis